Missling clearly states that the FDA's guidance of anchoring led to the use of RSBQ AUC, as it combines disease progression, not just EOT evaluation, which reduces the possibility of type 1 and type 2 errors. Therefore, it is more ROBUST and confirmatory.
Market Data 
Markets 
AI
